ImmuCell (ICCC) 10-Q 13 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 05, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	IMMUCELL CORP /DE/
Entity Central Index Key	811,641
Amendment Flag	false
Trading Symbol	ICCC
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		5,484,728

(Unaudited Condensed) Balance S

(Unaudited Condensed) Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 2,393,263	$ 3,798,811
Trade accounts receivable, net	853,972	1,344,022
Inventory	2,249,942	2,049,732
Prepaid expenses and other current assets	720,851	314,667
Total current assets	6,218,028	7,507,232
PROPERTY, PLANT AND EQUIPMENT, net	26,472,454	26,069,689
DEFERRED TAX ASSETS, net		472,726
INTANGIBLE ASSETS, net	138,504	152,832
GOODWILL	95,557	95,557
INTEREST RATE SWAPS	98,390
OTHER ASSETS	212,467	920
TOTAL ASSETS	33,235,400	34,298,956
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,060,684	1,723,270
Current portion of bank debt	842,637	316,629
Deferred revenue	24,100	24,100
Total current liabilities	1,927,421	2,063,999
LONG-TERM LIABILITIES:
Bank debt, net of current portion	8,634,854	8,639,021
Interest rate swaps		996
Total long-term liabilities	8,634,854	8,640,017
TOTAL LIABILITIES	10,562,275	10,704,016
CONTINGENT LIABILITIES AND COMMITMENTS (Note 16)
STOCKHOLDERS' EQUITY:
Common stock, $0.10 par value per share, 11,000,000 and 8,000,000 shares authorized, 5,662,645 and 5,662,645 shares issued and 5,484,728 and 5,476,197 shares outstanding, as of September 30, 2018 and December 31, 2017, respectively	566,265	566,265
Additional paid-in capital	22,712,753	22,458,219
(Accumulated deficit) retained earnings	(290,469)	978,973
Treasury stock, at cost, 177,917 and 186,448 shares as of September 30, 2018 and December 31, 2017, respectively	(389,217)	(407,879)
Accumulated other comprehensive income (loss)	73,793	(638)
Total stockholders' equity	22,673,125	23,594,940
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 33,235,400	$ 34,298,956

(Unaudited Condensed) Balance_2

(Unaudited Condensed) Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized	11,000,000	8,000,000
Common stock, shares issued	5,662,645	5,662,645
Common stock, shares outstanding	5,484,728	5,476,197
Treasury stock, shares	177,917	186,448

(Unaudited Condensed) Statement

(Unaudited Condensed) Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Product sales	$ 2,153,750	$ 2,004,961	$ 8,049,481	$ 7,298,496
Costs of goods sold	1,202,783	1,069,110	4,251,863	3,289,361
Gross margin	950,967	935,851	3,797,618	4,009,135
OPERATING EXPENSES (INCOME):
Product development expenses	908,793	585,834	2,253,620	1,312,456
Sales and marketing expenses	494,703	446,733	1,501,833	1,361,653
Administrative expenses	396,611	385,695	1,262,868	1,164,533
Gain on sale of assets	(700,000)		(700,000)
Operating activities, net	1,100,107	1,418,262	4,318,321	3,838,642
NET OPERATING (LOSS) INCOME	(149,140)	(482,411)	(520,703)	170,493
Other expenses, net	106,414	49,238	301,664	115,877
(LOSS) INCOME BEFORE INCOME TAXES	(255,554)	(531,649)	(822,367)	54,616
Income tax (benefit) expense	(5,598)	(192,303)	447,075	28,108
NET (LOSS) INCOME	$ (249,956)	$ (339,346)	$ (1,269,442)	$ 26,508
Basic weighted average common shares outstanding	5,483,880	4,992,803	5,481,095	4,896,782
Basic (loss) income per share	$ (0.05)	$ (0.07)	$ (0.23)	$ 0.01
Diluted weighted average common shares outstanding	5,483,880	4,992,803	5,481,095	4,999,245
Diluted (loss) income per share	$ (0.05)	$ (0.07)	$ (0.23)	$ 0.01

(Unaudited Condensed) Stateme_2

(Unaudited Condensed) Statements of Comprehensive (Loss) Income - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statements of Other Comprehensive Income [Abstract]
Net (loss) income	$ (249,956)	$ (339,346)	$ (1,269,442)	$ 26,508
Other comprehensive income:
Interest rate swaps, before taxes	19,107	2,850	99,386	5,342
Income tax applicable to interest rate swaps	(4,777)	(1,026)	(24,956)	(1,923)
Other comprehensive income, net of taxes	14,330	1,824	74,430	3,419
Total comprehensive (loss) income	$ (235,626)	$ (337,522)	$ (1,195,012)	$ 29,927

(Unaudited Condensed) Stateme_3

(Unaudited Condensed) Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (1,269,442)	$ 26,508
Adjustments to reconcile net (loss) income to net cash (used for) provided by operating activities:
Depreciation	938,416	627,141
Amortization	14,328	14,328
Non-cash interest expense	12,612	11,120
Deferred income taxes	447,770	9,112
Stock-based compensation	257,697	148,035
Gain on sale of assets	(700,000)
Gain on disposal of fixed assets		(3,663)
Recovery of uncollectible accounts, net		(17,643)
Changes in:
Trade accounts receivable, gross	490,050	141,114
Accrued interest income		24,013
Inventory	(200,210)	(605,126)
Prepaid expenses and other current assets	(156,185)	242,683
Other assets	(11,547)	(920)
Accounts payable and accrued expenses	(58,545)	262,270
Deferred revenue		(33,856)
Net cash (used for) provided by operating activities	(235,056)	845,116
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(1,931,146)	(13,079,386)
Payment of contingent royalties related to 2016 acquisition	(14,077)	(8,661)
Maturities of investments		5,699,000
Purchases of investments		(249,000)
Proceeds from sale of assets	250,000
Proceeds from sale of fixed assets		45,000
Net cash used for investing activities	(1,695,223)	(7,593,047)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from private placement, net		1,037,164
Proceeds from debt issuance	693,640	3,024,343
Debt principal repayments	(183,887)	(111,981)
Debt issuance costs	(522)	(63,358)
Proceeds from exercise of stock options	15,500	16,500
Tax benefits related to stock options		183
Net cash provided by financing activities	524,731	3,902,851
NET DECREASE IN CASH AND CASH EQUIVALENTS	(1,405,548)	(2,845,080)
BEGINNING CASH AND CASH EQUIVALENTS	3,798,811	5,150,344
ENDING CASH AND CASH EQUIVALENTS	2,393,263	2,305,264
CASH PAID FOR:
Income taxes	4,222	4,000
Interest	294,728	123,034
NON-CASH ACTIVITIES:
Change in capital expenditures included in accounts payable and accrued expenses	(589,964)	1,286,289
Net change in fair value of interest rate swaps	(74,430)	(3,419)
Fixed asset disposals, gross	$ 18,554	$ 1,500

Business Operations

Business Operations	9 Months Ended
	Sep. 30, 2018
Business Operations [Abstract]
BUSINESS OPERATIONS	1. BUSINESS OPERATIONS ImmuCell Corporation (the “Company”, “we”, “us”, “our”) is an animal health company whose purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. The Company was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with its initial public offering of common stock. We market products that provide immediate immunity to newborn dairy and beef cattle. We are developing product line extensions of our existing products and are in the late stages of developing a novel product that addresses mastitis, the most significant cause of economic loss to the dairy industry. These products help reduce the need to use traditional antibiotics in food producing animals. The Company is subject to certain risks associated with its stage of development including dependence on key individuals and third party providers of critical goods and services, competition from other larger companies, the successful sale of existing products and the development and acquisition of additional commercially viable products with appropriate regulatory approvals, where applicable. Based on our best estimates and projections, we believe that we have sufficient capital resources to continue operations for at least twelve months from the date of this filing. These and other risks to our Company are further detailed under Part II, Item 1A

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation We have prepared the accompanying unaudited condensed financial statements reflecting all adjustments that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB Accounting Standards Codification ™ (b) Cash and Cash Equivalents We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $2,140,960 and $3,546,529 as of September 30, 2018 and December 31, 2017, respectively. We account for investments in marketable securities in accordance with Codification Topic 320, Investments – Debt and Equity Securities (c) Inventory Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each monthly balance sheet date, we evaluate our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are reserved. Once inventory is written down and a new cost basis is established, it is not written back up if demand increases. We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products when practicable. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies. See Note 4. (d) Accounts Receivable Accounts receivable are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days. Past due accounts receivable are subject to an interest charge. Accounts receivable are written off when deemed uncollectible. The amount of accounts receivable written off during all periods reported was immaterial. Recoveries of accounts receivable previously written off are recorded as income when received. As of September 30, 2018, we determined that no allowance for doubtful accounts was necessary. (e) Property, Plant and Equipment We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed to produce the active pharmaceutical ingredient, Nisin, is being depreciated over 39 years from when a certificate of occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin production facility when it was placed in service during the third quarter of 2018. Approximately 89% of these assets are being depreciated over ten years. Significant repairs to fixed assets that benefit more than a current year are capitalized and depreciated over their useful lives. Insignificant repairs are expensed when incurred. See Note 6. (f) Intangible Assets and Goodwill We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships, non-compete agreements, and developed technology, each with defined useful lives. We have classified as goodwill the amounts paid in excess of fair value of the net assets (including tax attributes) acquired in purchase transactions. We assess the impairment of intangible assets and goodwill that have indefinite lives at the reporting unit level on an annual basis (as of December 31st) and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill are appropriately stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these judgments and require an adjustment to the recorded balance. No impairments were recorded during the nine-month period ended September 30, 2018 or the year ended December 31, 2017. See Notes 2(h), 7 and 8 for additional disclosures. (g) Fair Value Measurements In determining fair value measurements, we follow the provisions of Codification Topic 820, Fair Value Measurements and Disclosures Level 1 - Pricing inputs are quoted prices available in active markets for identical assets or liabilities as of the measurement date. Level 2 - Pricing inputs are quoted prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 3 - Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an asset’s or liability’s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the investment. We hold money market mutual funds in a brokerage account, which are classified as cash equivalents and measured at fair value. The fair value of these investments is based on their closing published net asset value. We assess the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During the nine-month period ended September 30, 2018 and the year ended December 31, 2017, there were no transfers between levels. As of September 30, 2018 and December 31, 2017, our Level 1 assets measured at fair value by quoted prices in active markets consisted of bank savings accounts and money market funds. As of September 30, 2018 and December 31, 2017, our interest rate swaps were classified as Level 2 and were measured by observable market data in combination with expected cash flows for each instrument. There were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2018 or December 31, 2017. As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 2,393,263 $ - $ - $ 2,393,263 Interest rate swaps $ - $ 98,390 $ - $ 98,390 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 3,798,811 $ - $ - $ 3,798,811 Liabilities: Interest rate swaps $ - $ (996 ) $ - $ (996 ) (h) Valuation of Long-Lived Assets We periodically evaluate our long-lived assets, consisting principally of fixed assets and amortizable intangible assets, for potential impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. We evaluate our long-lived assets whenever events or circumstances suggest that the carrying amount of an asset or group of assets may not be recoverable. No impairment was recognized during the nine-month period ended September 30, 2018 or the year ended December 31, 2017. (i) Concentration of Risk Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table: During the Three-Month Periods Ended During the Nine-Month Periods Ended 2018 2017 2018 2017 Animal Health International, Inc. 50 % 44 % 42 % 42 % MWI Animal Health 23 % 22 % 22 % 23 % ANIMART LLC * 10 % 10 % * *Amount is less than 10%. Trade accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table: As of September 30, As of December 31, Animal Health International, Inc. 58 % 40 % MWI Animal Health 25 % 29 % (j) Interest Rate Swap Agreements All derivatives are recognized on the balance sheet at their fair value. We entered into interest rate swap agreements in 2010 and 2015. On the dates the agreements were entered into, we designated the derivatives as hedges of the variability of cash flows to be paid related to our long-term debt. The agreements have been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreements are recorded as comprehensive income (loss), until earnings are affected by the variability of cash flows (e.g., when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreements and the related hedged items. We also formally assess, both at the interest rate swap agreements’ inception and on an ongoing basis, whether the agreements are highly effective in offsetting changes in cash flow of hedged items. See Note 10. (k) Revenue Recognition We sell products that provide immediate immunity to newborn dairy and beef cattle. For periods ended on and before December 31, 2017, we recognized revenue in accordance with Accounting Standards Codification (ASC) 605 when four criteria were met. These included i) persuasive evidence that an arrangement existed, ii) delivery had occurred, iii) our price was fixed and determinable and iv) collectability was reasonably assured. For periods beginning on January 1, 2018, we recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers (l) Expense Recognition In 2018, we adopted ASC 340-40, Accounting for Other Assets and Deferred Costs (m) Income Taxes We account for income taxes in accordance with Codification Topic 740, Income Taxes (n) Stock-Based Compensation We account for stock-based compensation in accordance with Codification Topic 718, Compensation-Stock Compensation (o) Net (Loss) Income Per Common Share Net (loss) income per common share has been computed in accordance with Codification Topic 260-10, Earnings Per Share. During the Three-Month During the Nine-Month Periods Ended Periods Ended 2018 2017 2018 2017 Weighted average number of shares outstanding 5,483,880 4,992,803 5,481,095 4,896,782 Effect of dilutive stock options - - - 102,463 Diluted number of shares outstanding 5,483,880 4,992,803 5,481,095 4,999,245 Outstanding stock options not included in the calculation because the effect would be anti-dilutive 489,000 367,000 489,000 63,000 (p) Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those estimates. Changes in estimates are recorded during the period in which they become known. Significant estimates include our inventory valuation, valuation of goodwill and long-lived assets, accrued expenses, costs of goods sold, and useful lives of intangible assets. (q) New Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2018
Cash and Cash Equivalents [Abstract]
CASH AND CASH EQUIVALENTS	3. CASH AND CASH EQUIVALENTS Cash and cash equivalents consisted of the following: As of September 30, 2018 As of December 31, 2017 Cash and cash equivalents $ 2,393,263 $ 3,798,811 Short-term investments were liquidated during 2017 to finance the investment in our Nisin production facility. The cost of securities sold is determined based on the specific identification method. Realized gains and losses, and declines in value judged to be other than temporary, are included in investment income. We are required by bank debt covenant to maintain at least $2,000,000 of otherwise unrestricted cash, cash equivalents and short-term investments.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2018
Inventory [Abstract]
INVENTORY	4. INVENTORY Inventory consisted of the following: As of September 30, As of December 31, Raw materials $ 416,139 $ 483,329 Work-in-process 1,310,526 1,349,649 Finished goods 523,277 216,754 Total $ 2,249,942 $ 2,049,732

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2018
Prepaid Expenses and Other Current Assets [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	5. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: As of September 30, As of December 31, Other receivables (1) $ 390,207 $ 149,590 Prepaid expenses 296,380 130,813 Security deposits (2) 34,264 34,264 Total $ 720,851 $ 314,667 (1) This amount includes $250,000 due from a third party for the sale of assets. See Note 13. (2) This amount consists of the current portion of escrow funds held against certain construction performance requirements for our Nisin production facility.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	6. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: Estimated (in years) As of September 30, As of December 31, Laboratory and manufacturing equipment 3-10 $ 15,042,596 $ 5,511,452 Building and improvements 10-39 17,006,716 16,966,728 Office furniture and equipment 3-10 734,887 698,877 Construction in progress 34,786 8,315,436 Land 516,867 518,999 Property, plant and equipment, gross 33,335,852 32,011,492 Accumulated depreciation (6,863,398 ) (5,941,803 ) Property, plant and equipment, net $ 26,472,454 $ 26,069,689 As of December 31, 2017, construction in progress consisted principally of payments for equipment to be used in our Nisin production facility. Approximately $18,554 and $435,448 of property, plant and equipment, gross, was disposed of during the nine-month period ended September 30, 2018 and the year ended December 31, 2017, respectively.

Business Acquisition

Business Acquisition	9 Months Ended
	Sep. 30, 2018
Business Acquisition [Abstract]
BUSINESS ACQUISITION	7. BUSINESS ACQUISITION On January 4, 2016, we acquired certain business assets and processes from DAY 1 ™ First Defense Ò Tri-Shield First Defense Ò

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2018
Intangible Assets [Abstract]
INTANGIBLE ASSETS	8. INTANGIBLE ASSETS The intangible assets described in Note 7 are being amortized to cost of goods sold over their useful lives, which are estimated to be 10 years. Intangible amortization expense was $4,776 during the three-month periods ended September 30, 2018 and 2017 and $14,328 during the nine-month periods ended September 30, 2018 and 2017. The net value of these intangibles was $138,504 and $152,832 as of September 30, 2018 and December 31, 2017, respectively. A summary of intangible amortization expense estimated for the periods subsequent to September 30, 2018 is as follows: Period Amount Three-month period ending December 31, 2018 $ 4,776 Year ending December 31, 2019 19,104 Year ending December 31, 2020 19,104 Year ending December 31, 2021 19,104 Year ending December 31, 2022 19,104 After December 31, 2022 57,312 Total $ 138,504 Intangible assets as of September 30, 2018 consisted of the following: Gross Carrying Value Accumulated Amortization Net Book Value Developed technology $ 184,100 $ (50,628 ) $ 133,472 Customer relationships 1,300 (357 ) 943 Non-compete agreements 5,640 (1,551 ) 4,089 Total $ 191,040 $ (52,536 ) $ 138,504 Intangible assets as of December 31, 2017 consisted of the following: Gross Carrying Value Accumulated Amortization Net Book Value Developed technology $ 184,100 $ (36,820 ) $ 147,280 Customer relationships 1,300 (260 ) 1,040 Non-compete agreements 5,640 (1,128 ) 4,512 Total $ 191,040 $ (38,208 ) $ 152,832

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Accounts Payable and Accrued Expenses [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following: As of September 30, As of December 31, Accounts payable – capital $ 51,426 $ 641,389 Accounts payable – trade 515,785 580,456 Accrued payroll 281,036 254,743 Accrued professional fees 95,575 64,200 Accrued other 116,862 182,482 Total $ 1,060,684 $ 1,723,270

Bank Debt

Bank Debt	9 Months Ended
	Sep. 30, 2018
Bank Debt [Abstract]
BANK DEBT	10. BANK DEBT We have in place five credit facilities and a line of credit with TD Bank N.A. that are secured by substantially all of our assets and are subject to certain restrictions and financial covenants. The first note (Loan #1) is not to exceed 80% of the appraised value of our corporate headquarters and production and research facility at 56 Evergreen Drive in Portland. Proceeds of $1,000,000 were received during the third quarter of 2010 with monthly principal and interest payments due for ten years. Based on a fifteen-year amortization schedule, a balloon principal payment of $451,885 will be due during the third quarter of 2020. As of September 30, 2018, $579,485 was outstanding under this first note (Loan #1). Proceeds from a $2,500,000 second mortgage on our corporate headquarters (Loan #2) were received during the third quarter of 2015 with monthly principal and interest payments due for ten years. Based on a twenty-year amortization schedule, a balloon principal payment of approximately $1,550,000 will be due during the third quarter of 2025. As of September 30, 2018, $2,256,028 was outstanding under Loan #2. During the first quarter of 2016, we entered into two additional credit facilities (Loans #3 and #4) aggregating up to approximately $4,500,000. As a result of loan amendments entered into the during the first quarter of 2017, these two credit facilities were increased to up to $6,500,000, subject to certain restrictions set forth in the agreements. The third note (Loan #3) is comprised of a construction loan of up to $3,940,000 and not to exceed 80% of the cost of the equipment to be installed in our commercial-scale Nisin production facility at 33 Caddie Lane in Portland. As amended, interest only was payable at a variable rate equal to the one-month LIBOR (adjusted at each monthly payment date) plus a margin of 2.25% (which was equal to approximately 4.35% for the one-month period beginning October 1, 2018) through September 2018, at which time the loan converted to a seven-year term loan facility at the same variable interest rate with monthly principal and interest payments due based on a seven-year amortization schedule. As of September 30, 2018, $3,940,000 was outstanding under this third note. The fourth note (Loan #4) is comprised of a construction loan of up to $2,560,000 and not to exceed 80% (75% prior to the 2017 amendments) of the appraised value of our commercial-scale Nisin production facility. As amended, interest only was payable at a variable rate equal to the one-month LIBOR (adjusted at each monthly payment date) plus a margin of 2.25% (which was equal to approximately 4.35% for the one-month period beginning October 1, 2018) through March 2018, at which time the loan converted to a term loan facility at the same variable interest rate with monthly principal and interest payments due for ten years. Based on a twenty-year amortization schedule, a balloon principal payment of approximately $1,408,000 will be due during the first quarter of 2027. As of September 30, 2018, $2,496,000 was outstanding under this fourth note. The fifth note (Loan #5) is a mortgage that is secured by the 4,114 square foot warehouse and storage facility we acquired adjacent to our Nisin production facility. Proceeds of $340,000 were received during the first quarter of 2017. This note bears interest at a variable rate equal to the one-month LIBOR (adjusted at each monthly payment date) plus a margin of 2.25% (which was equal to approximately 4.31% for the one-month period beginning September 16, 2018) with monthly principal and interest payments due for ten years. Based on a twenty-year amortization schedule, a balloon principal payment of approximately $206,000 will be due during the first quarter of 2027. As of September 30, 2018, $323,333 was outstanding under this fifth note. We are required by bank debt covenant to maintain at least $2,000,000 of otherwise unrestricted cash, cash equivalents and short-term investments. We hedged our interest rate exposures on Loan #1 and Loan #2 with interest rate swap agreements that effectively converted floating interest rates based on the one-month LIBOR plus a margin of 3.25% and 2.25% to the fixed rates of 6.04% and 4.38%, respectively. As of September 30, 2018, the variable rates on these two mortgage notes were approximately 5.40% and 4.43%, respectively. All derivatives are recognized on the balance sheet at their fair value. At the time of the closings and thereafter, the agreements were determined to be highly effective in hedging the variability of the identified cash flows and have been designated as cash flow hedges of the variability in the hedged interest payments. Changes in the fair value of the interest rate swap agreements are recorded in other comprehensive income, net of taxes. The original notional amounts of the interest rate swap agreements of $1,000,000 and $2,500,000 amortize in accordance with the amortization of the mortgage notes. The notional amount of the interest rate swaps was $2,835,513 as of September 30, 2018. The fair values of the interest rate swaps have been determined using observable market-based inputs or unobservable inputs that are corroborated by market data. Accordingly, the interest rate swaps are classified as level 2 within the fair value hierarchy provided in Codification Topic 820, Fair Value Measurements and Disclosures During the Three-Month Periods Ended During the Nine-Month Periods Ended 2018 2017 2018 2017 Payments required by interest rate swaps $ 1,391 $ 8,115 $ 9,499 $ 29,834 Other comprehensive income, net of taxes $ 14,330 $ 1,824 $ 74,430 $ 3,419 In connection with the credit facilities entered into during the third quarters of 2010 and 2015, we incurred debt issue costs of $26,489 and $34,125, respectively. In connection with the credit facilities and amendments thereto entered into during the first quarters of 2016 and 2017, we incurred debt issue costs of $46,734 and $66,622, respectively. The 2017 amendments to the 2016 agreements were accounted for as modifications. The amortization of debt issuance costs is being recorded as a component of other expenses and is being amortized over the terms of the respective credit facilities. Debt proceeds received and principal repayments made during the three-month periods ended September 30, 2018 and 2017 are reflected in the following table by loan: During the Three-Month Periods Ended September 30, 2018 September 30, 2017 Proceeds from Debt Issuance Debt Principal Repayments Proceeds from Debt Issuance Debt Principal Repayments Loan #1 $ - $ (16,219 ) $ - $ (15,264 ) Loan #2 - (21,279 ) - (20,343 ) Loan #3 426,499 - 2,184,343 - Loan #4 - (32,000 ) - - Loan #5 - (2,640 ) - (2,802 ) Total $ 426,499 $ (72,138 ) $ 2,184,313 $ (38,409 ) Debt proceeds received and principal repayments made during the nine-month periods ended September 30, 2018 and 2017 are reflected in the following table by loan: During the Nine-Month Periods Ended September 30, 2018 September 30, 2017 Proceeds from Debt Issuance Debt Principal Repayments Proceeds from Debt Issuance Debt Principal Repayments Loan #1 $ - $ (47,995 ) $ - $ (45,168 ) Loan #2 - (63,837 ) - (61,029 ) Loan #3 426,499 - 2,684,343 - Loan #4 267,141 (64,000 ) - - Loan #5 - (8,055 ) 340,000 (5,784 ) Total $ 693,640 $ (183,887 ) $ 3,024,343 $ (111,981 ) Principal payments (net of debt issuance costs) due under bank loans outstanding as of September 30, 2018 (excluding our $500,000 line of credit) are reflected in the following table by the year that payments are due: Three-Months ending 12/31/2018 Year Year Year Year After Total Loan #1 $ 16,881 $ 68,908 $ 493,696 $ - $ - $ - $ 579,485 Loan #2 22,260 89,997 94,005 98,538 103,077 1,848,151 2,256,028 Loan #3 (1) 140,714 562,857 562,857 562,857 562,857 1,547,858 3,940,000 Loan #4 (1) 32,000 128,000 128,000 128,000 128,000 1,952,000 2,496,000 Loan #5 (2) 2,874 11,812 12,332 12,874 13,441 270,000 323,333 Total $ 214,729 $ 861,574 $ 1,290,890 $ 802,269 $ 807,375 $ 5,618,009 $ 9,594,846 Debt Issuance Costs (117,355 ) Total $ 9,477,491 (1) These notes bear interest at a variable rate equal to the one-month LIBOR plus a margin of 2.25%. Figures in this table are estimated using an interest rate of approximately 4.35%. The actual interest rate and principal payments will be different. (2) This note bears interest at a variable rate equal to the one-month LIBOR plus a margin of 2.25%. Figures in this table are estimated using an interest rate of approximately 4.31%. The actual interest rate and principal payments will be different. During the third quarter of 2010, we entered into a $500,000 line of credit with TD Bank N.A., which has been renewed approximately annually since then and is available as needed and has been extended through May 31, 2020. There was no outstanding balance under this line of credit as of September 30, 2018 or December 31, 2017. Interest on borrowings against the line of credit is variable at the higher of 4.25% per annum or the one-month LIBOR plus 3.5% per annum.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2018
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	11. STOCKHOLDERS’ EQUITY On October 28, 2015, we filed a registration statement on Form S-3 (File No. 333-207635) with the Securities and Exchange Commission (SEC) for the potential issuance of up to $10,000,000 in equity securities (subject to certain limitations). This registration statement became effective on November 10, 2015. Under this form of registration statement, we were limited within a twelve-month period to raising gross proceeds of no more than one-third of the market capitalization of our common stock (as determined by the high price of our common stock within the preceding 60 days leading up to a sale of securities) held by non-affiliates (non-insiders) of the Company. On February 3, 2016, we sold 1,123,810 shares of common stock at a price to the public of $5.25 per share in an underwritten public offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of approximately $5,900,000 and resulting in net proceeds to the Company of approximately $5,313,000 (after deducting underwriting discounts and offering expenses incurred in connection with the equity financing). On October 21, 2016, we closed on a private placement of 659,880 shares of common stock to nineteen institutional and accredited investors at $5.25 per share, raising gross proceeds of approximately $3,464,000 and resulting in net proceeds to the Company of approximately $3,161,000 (after deducting placement agent fees and other expenses incurred in connection with the equity financing). On July 27, 2017, we issued 200,000 shares of our common stock at a price of $5.25 per share to two related investors pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $1,050,000 and resulting in net proceeds of approximately $1,034,000 (after deducting expenses incurred in connection with the equity financing). On December 21, 2017, we sold 417,807 shares of common stock at a price to the public of $7.30 per share in an underwritten public offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of approximately $3,050,000 and resulting in net proceeds to the Company of approximately $2,734,000 (after deducting underwriting discounts and offering expenses incurred in connection with the equity financing). At the June 15, 2016 Annual Meeting of Stockholders, we reported that our stockholders voted to approve an amendment to the Company’s Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 8,000,000 to 10,000,000. After careful consideration, we determined that the method of voting instructions described in our Proxy Statement was not consistent with the way the votes were actually recorded in accordance with stock exchange rules. Therefore, during the second quarter of 2017, we elected to treat the amendment as ineffective, and there was no increase in our authorized common stock. At the June 14, 2018 Annual Meeting of Stockholders, our stockholders voted to approve an amendment to the Company’s Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 8,000,000 to 11,000,000. In June 2000, our stockholders approved the 2000 Stock Option and Incentive Plan (the “2000 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at i) no less than fair market value on the date of grant in the case of incentive stock options and ii) no less than 85% of fair market value on the date of grant in the case of non-qualified stock options. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case by case basis. Originally, 250,000 shares of common stock were reserved for issuance under the 2000 Plan. The stockholders of the Company approved an increase in this number to 500,000 shares in June 2001. All options granted under the 2000 Plan expire no later than ten years from the date of grant. The 2000 Plan expired in February 2010, after which date no further options could be granted under the 2000 Plan. However, outstanding options under the 2000 Plan may be exercised in accordance with their terms. In June 2010, our stockholders approved the 2010 Stock Option and Incentive Plan (the “2010 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2010 Plan and subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case by case basis. All options granted under the 2010 Plan expire no later than ten years from the date of grant. The 2010 Plan expires in June 2020, after which date no further options could be granted under the 2010 Plan. However, options outstanding under the 2010 Plan at that time could be exercised in accordance with their terms. In June 2017, our stockholders approved the 2017 Stock Option and Incentive Plan (the “2017 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2017 Plan. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case by case basis. All options granted under the 2017 Plan expire no later than ten years from the date of grant. The 2017 Plan expires in March 2027, after which date no further options could be granted under the 2017 Plan. However, options outstanding under the 2017 Plan at that time could be exercised in accordance with their terms. Activity under the stock option plans described above was as follows: 2000 Plan 2010 Plan 2017 Plan Weighted Aggregate Intrinsic Value (1) Outstanding at December 31, 2016 126,500 124,500 - $ 3.89 $ 516,990 Grants - 141,000 - $ 5.92 Terminations (5,000 ) (16,000 ) - $ 5.68 Exercises (4,000 ) (7,000 ) - $ 3.47 Outstanding at December 31, 2017 117,500 242,500 - $ 4.58 $ 1,513,980 Grants - 44,500 122,500 $ 7.39 Terminations - (15,000 ) (11,000 ) $ 6.55 Exercises (10,000 ) (2,000 ) - $ 3.38 Outstanding at September 30, 2018 107,500 270,000 111,500 $ 5.47 $ 1,400,530 Vested at September 30, 2018 107,500 36,500 - $ 2.59 $ 827,070 Vested and expected to vest at September 30, 2018 107,500 270,000 111,500 $ 5.47 $ 1,400,530 Reserved for future grants - 1,000 188,500 (1) Intrinsic value is the difference between the fair market value as of the date indicated and as of the date of the option grant. During the nine-month period ended September 30, 2018, five employees exercised stock options covering 12,000 shares. Four thousand of these options were exercised for cash, resulting in total proceeds of $15,490, and 8,000 of these options were exercised by the surrender of 3,469 shares of common stock with a fair market value of $25,040 at the time of exercise and $10 in cash. During the year ended December 31, 2017, six employees exercised stock options covering 11,000 shares for cash, resulting in total proceeds of $49,560. The weighted average remaining life of the options outstanding under the 2000 Plan, the 2010 Plan and the 2017 Plan as of September 30, 2018 was approximately five years and six months. The weighted average remaining life of the options exercisable under these plans as of September 30, 2018 was approximately nine months. The exercise prices of the options outstanding as of September 30, 2018 ranged from $1.70 to $8.90 per share. The 167,000 stock options granted during the nine-month period ended September 30, 2018 had exercise prices between $6.81 and $8.43 per share. The 141,000 stock options granted during the year ended December 31, 2017 had exercise prices between $5.33 and $8.90 per share. The aggregate intrinsic value of options exercised during 2018 and 2017 approximated $46,790 and $43,470, respectively. The weighted-average grant date fair values of options granted during 2018 and 2017 were $4.21 and $3.51 per share, respectively. As of September 30, 2018, total unrecognized stock-based compensation related to non-vested stock options aggregated $795,891, which will be recognized over a weighted average period of one year and eleven months. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following weighted-average assumptions for the three-month and nine-month periods ended September 30, 2018 and for the year ended December 31, 2017: During the Three-Month Period Ended September 30, 2018 During the Nine-Month Period Ended September 30, 2018 During the Year Ended December 31, 2017 Risk-free interest rate 2.5 % 2.6 % 1.9 % Dividend yield 0 % 0 % 0 % Expected volatility 57 % 57 % 61 % Expected life 6.5 years 6.5 years 6.5 years The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term, while the other assumptions are derived from averages of our historical data. Common Stock Rights Plan In September 1995, our Board of Directors adopted a Common Stock Rights Plan (the “Rights Plan”) and declared a dividend of one common share purchase right (a “Right”) for each of the then outstanding shares of the common stock of the Company as well as subsequently issued shares of such common stock. Each Right entitles the registered holder to purchase from the Company one share of common stock at an initial purchase price of $70.00 per share, subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement between the Company and American Stock Transfer & Trust Co., as Rights Agent. The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date). Upon the Distribution Date, the holder of each Right not owned by the Acquiring Person would be entitled to purchase common stock at a discount to the initial purchase price of $70.00 per share, effectively equal to one half of the market price of a share of common stock on the date the Acquiring Person becomes an Acquiring Person. If, after the Distribution Date, the Company should consolidate or merge with any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company’s common stock were changed or exchanged into the securities of any other entity, or if more than 50% of the Company’s assets or earning power were sold, each Right would entitle its holder to purchase, at the Rights’ then-current purchase price, a number of shares of the acquiring company’s common stock having a market value at that time equal to twice the Right’s exercise price. At any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of 50% or more of the outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to 14 days following the date that any person or group becomes an Acquiring Person (subject to extension by the Board of Directors), the Board of Directors of the Company may redeem the then outstanding Rights in whole, but not in part, at a price of $0.005 per Right, subject to adjustment. At various times over the years, our Board of Directors has voted to authorize amendments of the Rights Agreement to extend the Final Expiration Date, which is currently September 19, 2022. Our Board of Directors also has voted to authorize amendments to increase the ownership threshold for determining “Acquiring Person” status to 20%. During the second quarter of 2015, our Board of Directors also voted to authorize an amendment to remove a provision that prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than 20% of our stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with pre-existing directors. We did this because such provisions have come to be viewed with disfavor by Delaware courts. Each time that we made such amendments we entered into amendments to the Rights Agreement with the Rights Agent reflecting such extensions, threshold increases or provision changes. No other changes have been made to the terms of the Rights or the Rights Agreement.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2018
Revenue [Abstract]
REVENUE	12. REVENUE We primarily offer the First Defense Ò product line to dairy and beef producers to prevent scours in newborn calves. Generally, our products are promoted to veterinarians and dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select international regions and may expand this international reach in the future. The demand for animal protein, that must be produced efficiently while insuring food quality and safety, increases as the human population grows. Our products help address the growing human health concern about using less antibiotics in food-producing animals. There were no material changes between the allocation and timing of revenue recognition during the three-month and nine-month periods ended September 30, 2018 (under ASC 606) and the three-month and nine-month periods ended September 30, 2017 (under ASC 605). We do not have any contract assets such as contracts for which we have satisfied the performance obligations but do not yet have the right to bill for or contract liabilities such as customer advances. All trade receivables on our balance sheet are from contracts with customers. We incur no material costs to obtain contracts. As of March 31, 2018, we had a backlog of orders (representing purchase orders received from customers which were not fulfilled or paid) worth approximately $1,245,000 for the First Defense ® product line. Before June 30, 2018 we cleared all of this backlog that was related to orders for our bivalent formats of the ® product line (which will be re-branded as ™ Ò ). As of September 30, 2018, we had a backlog of orders for Tri-Shield First Defense ® worth approximately $301,000. We do not have any contract assets such as contracts for which we have satisfied the performance obligations but do not yet have the right to bill for or contract liabilities such as customer advances. All trade receivables on our condensed financial statements are from contracts with customers. We incur no material costs to obtain a contract. T he following table presents our product sales disaggregated by geographic area: During the Three-Month Period Ended September 30, During the Nine-Month Period Ended September 30, 2018 2018 United States $ 1,893,483 $ 7,033,232 Other 260,267 1,016,249 Total product sales $ 2,153,750 $ 8,049,481 The following table presents our product sales disaggregated by major product category: During the Three-Month Period Ended September 30, During the Nine-Month Period Ended September 30, 2018 2018 First Defense Ò $ 2,118,655 $ 7,783,006 Other animal health 35,095 266,475 Total product sales $ 2,153,750 $ 8,049,481

Gain on Sale of Assets

Gain on Sale of Assets	9 Months Ended
	Sep. 30, 2018
Gain On Sale Of Assets [Abstract]
GAIN ON SALE OF ASSETS	13. GAIN ON SALE OF ASSETS During the third quarter of 2018, we sold the assets underlying our water diagnostic product for $700,000. This sale of assets was recognized as an operating activity at that time in accordance with ASC 610: Other Income Consolidation

Other Expenses, Net

Other Expenses, Net	9 Months Ended
	Sep. 30, 2018
Other Expenses, Net [Abstract]
OTHER EXPENSES, NET	14. OTHER EXPENSES, NET Other expenses, net, consisted of the following: During the Three-Month Periods Ended During the Nine-Month Periods Ended 2018 2017 2018 2017 Interest expense $ 109,651 $ 53,168 $ 311,934 $ 136,563 Interest income (3,237 ) (2,983 ) (10,270 ) (15,358 ) Other gains - (947 ) - (5,328 ) Other expenses, net $ 106,414 $ 49,238 $ 301,664 $ 115,877

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Taxes [Abstract]
INCOME TAXES	15. INCOME TAXES Our income tax benefit aggregated $5,598 and $192,303 (amounting to 2% and 36% of our (loss) before income taxes, respectively) for the three-month periods ended September 30, 2018 and 2017, respectively. Our income tax expense aggregated $447,075 and $28,108 (amounting to 54% and 51% of our (loss) income before income taxes, respectively) for the nine-month periods ended September 30, 2018 and 2017, respectively. As of September 30, 2018, we had federal net operating loss carryforwards of approximately $1,700,000 that expire in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards of approximately $429,000 that expire in 2037 (if not utilized before then). Additionally, we had federal general business tax credit carryforwards of approximately $335,000 that expire in 2027 through 2037 (if not utilized before then) and state tax credit carryforwards of approximately $294,000 that expire in 2023 through 2037 (if not utilized before then). The $965,000 licensing payment that we made during the fourth quarter of 2004 was treated as an intangible asset and is being amortized over 15 years, for tax return purposes only. Approximately $1,112,000 of our investment in a small-scale facility to produce the Drug Substance (our Active Pharmaceutical Ingredient, Nisin) was expensed as incurred for our books from 2013 to 2015. Included in this amount is approximately $820,000 that was capitalized and is being depreciated over statutory periods for tax return purposes only. The Tax Cuts and Jobs Act was signed into law in December 2017. This legislation made significant changes in the U.S. tax law, including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks and a repeal of the corporate alternative minimum tax. The legislation reduced the U.S. corporate tax rate from the prior rate of 34% to 21%. As a result of the enacted law, we were required to revalue deferred tax assets and liabilities at the enacted rate in 2017. The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable. During the second quarter of 2018, we recorded a valuation allowance of $563,252 against these deferred tax assets because we have incurred a net loss for six consecutive quarters and have not been profitable on a year-to-date basis since the nine-month period ended September 30, 2017 and project additional net losses for some period going forward before returning to profitability. During the third quarter of 2018, we increased this valuation allowance by $315,725 to $878,977. While we consider future taxable income and feasible tax planning strategies in assessing the need for a valuation allowance, in the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, a reduction of the valuation allowance would increase income in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our net deferred tax asset in the future, an increase to the valuation allowance would be charged to income in the period such determination was made. Net operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the event of a change in ownership of the Company, as defined. The Company files income tax returns in the U.S. federal jurisdiction and several state jurisdictions. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 2014. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying financial statements.

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	9 Months Ended
	Sep. 30, 2018
Contingent Liabilities and Commitments [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	16. CONTINGENT LIABILITIES AND COMMITMENTS Our bylaws, as amended, in effect provide that the Company will indemnify its officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings to each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically unlimited and is impossible to determine. We maintain directors’ and officers’ liability insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460 , Guarantees The development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted against us during the normal course of business. We are aware of no such claims against us as of the date of this filing. We feel that we have reasonable levels of liability insurance to support our operations. We enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations, and based on our analysis of the nature of the risks involved, we believe that the fair value of the liabilities potentially arising under these agreements is minimal. Accordingly, we have recorded no liabilities for such obligations as of September 30, 2018. We are committed to purchasing certain key parts (syringes) and services (formulation, filling and packaging of Drug Product) pertaining to our mastitis product exclusively from two contractors. If we do not achieve regulatory approval by December 17, 2019 and the contract counter party were to exercise its right to terminate the agreement, we would be liable for a $100,000 termination fee under one of such agreements and would need to identify and reach agreement with another party to perform these services for us, unless we make an investment to perform these services for ourselves. During the second quarter of 2009, we entered into an exclusive and perpetual license (unless terminated for cause) with the Baylor College of Medicine covering the underlying rotavirus vaccine technology used to generate the specific antibodies for our product line extension, Tri-Shield First Defense Ò We have committed $682,000 to the purchase of inventory, $77,000 to capital expeditures and $142,000 to other obligations as of September 30, 2018.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2018
Segment Information [Abstract]
SEGMENT INFORMATION	17. SEGMENT INFORMATION We principally operate in the business segment described in Note 1. Pursuant to Codification Topic 280, Segment Reporting Sales of the First Defense Ò

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	18 . RELATED PARTY TRANSACTIONS Dr. David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc. (formerly Stearns Veterinary Outlet, Inc.), a domestic distributor of ImmuCell products (the First Defense Ò CMT

Employee Benefits

Employee Benefits	9 Months Ended
	Sep. 30, 2018
Employee Benefits [Abstract]
EMPLOYEE BENEFITS	19. EMPLOYEE BENEFITS We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. We currently match 100% of the first 3% of each employee’s salary that is contributed to the Plan and 50% of the next 2% of each employee’s salary that is contributed to the Plan. Under this matching plan, we paid $25,644 and $21,083 into the plan for the three-month periods ended September 30, 2018 and 2017, respectively, and $79,655 and $64,105 for the nine-month periods ended September 30, 2018 and 2017, respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	20. SUBSEQUENT EVENTS We have evaluated subsequent events through the time of filing on November 13, 2018, the date we have issued this Quarterly Report on Form 10-Q. As of such date, there were no material, reportable subsequent events.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation We have prepared the accompanying unaudited condensed financial statements reflecting all adjustments that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB Accounting Standards Codification ™
Cash and Cash Equivalents	(b) Cash and Cash Equivalents We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $2,140,960 and $3,546,529 as of September 30, 2018 and December 31, 2017, respectively. We account for investments in marketable securities in accordance with Codification Topic 320, Investments – Debt and Equity Securities
Inventory	(c) Inventory Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each monthly balance sheet date, we evaluate our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are reserved. Once inventory is written down and a new cost basis is established, it is not written back up if demand increases. We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products when practicable. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies. See Note 4.
Accounts Receivable	(d) Accounts Receivable Accounts receivable are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days. Past due accounts receivable are subject to an interest charge. Accounts receivable are written off when deemed uncollectible. The amount of accounts receivable written off during all periods reported was immaterial. Recoveries of accounts receivable previously written off are recorded as income when received. As of September 30, 2018, we determined that no allowance for doubtful accounts was necessary.
Property, Plant and Equipment	(e) Property, Plant and Equipment We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed to produce the active pharmaceutical ingredient, Nisin, is being depreciated over 39 years from when a certificate of occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin production facility when it was placed in service during the third quarter of 2018. Approximately 89% of these assets are being depreciated over ten years. Significant repairs to fixed assets that benefit more than a current year are capitalized and depreciated over their useful lives. Insignificant repairs are expensed when incurred. See Note 6.
Intangible Assets and Goodwill	(f) Intangible Assets and Goodwill We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships, non-compete agreements, and developed technology, each with defined useful lives. We have classified as goodwill the amounts paid in excess of fair value of the net assets (including tax attributes) acquired in purchase transactions. We assess the impairment of intangible assets and goodwill that have indefinite lives at the reporting unit level on an annual basis (as of December 31st) and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill are appropriately stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these judgments and require an adjustment to the recorded balance. No impairments were recorded during the nine-month period ended September 30, 2018 or the year ended December 31, 2017. See Notes 2(h), 7 and 8 for additional disclosures.
Fair Value Measurements	(g) Fair Value Measurements In determining fair value measurements, we follow the provisions of Codification Topic 820, Fair Value Measurements and Disclosures Level 1 - Pricing inputs are quoted prices available in active markets for identical assets or liabilities as of the measurement date. Level 2 - Pricing inputs are quoted prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 3 - Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an asset’s or liability’s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the investment. We hold money market mutual funds in a brokerage account, which are classified as cash equivalents and measured at fair value. The fair value of these investments is based on their closing published net asset value. We assess the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During the nine-month period ended September 30, 2018 and the year ended December 31, 2017, there were no transfers between levels. As of September 30, 2018 and December 31, 2017, our Level 1 assets measured at fair value by quoted prices in active markets consisted of bank savings accounts and money market funds. As of September 30, 2018 and December 31, 2017, our interest rate swaps were classified as Level 2 and were measured by observable market data in combination with expected cash flows for each instrument. There were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2018 or December 31, 2017. As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 2,393,263 $ - $ - $ 2,393,263 Interest rate swaps $ - $ 98,390 $ - $ 98,390 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 3,798,811 $ - $ - $ 3,798,811 Liabilities: Interest rate swaps $ - $ (996 ) $ - $ (996 )
Valuation of Long-Lived Assets	(h) Valuation of Long-Lived Assets We periodically evaluate our long-lived assets, consisting principally of fixed assets and amortizable intangible assets, for potential impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. We evaluate our long-lived assets whenever events or circumstances suggest that the carrying amount of an asset or group of assets may not be recoverable. No impairment was recognized during the nine-month period ended September 30, 2018 or the year ended December 31, 2017.
Concentration of Risk	(i) Concentration of Risk Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table: During the Three-Month Periods Ended During the Nine-Month Periods Ended 2018 2017 2018 2017 Animal Health International, Inc. 50 % 44 % 42 % 42 % MWI Animal Health 23 % 22 % 22 % 23 % ANIMART LLC * 10 % 10 % * *Amount is less than 10%. Trade accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table: As of September 30, As of December 31, Animal Health International, Inc. 58 % 40 % MWI Animal Health 25 % 29 %
Interest Rate Swap Agreements	(j) Interest Rate Swap Agreements All derivatives are recognized on the balance sheet at their fair value. We entered into interest rate swap agreements in 2010 and 2015. On the dates the agreements were entered into, we designated the derivatives as hedges of the variability of cash flows to be paid related to our long-term debt. The agreements have been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreements are recorded as comprehensive income (loss), until earnings are affected by the variability of cash flows (e.g., when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreements and the related hedged items. We also formally assess, both at the interest rate swap agreements’ inception and on an ongoing basis, whether the agreements are highly effective in offsetting changes in cash flow of hedged items. See Note 10.
Revenue Recognition	(k) Revenue Recognition We sell products that provide immediate immunity to newborn dairy and beef cattle. For periods ended on and before December 31, 2017, we recognized revenue in accordance with Accounting Standards Codification (ASC) 605 when four criteria were met. These included i) persuasive evidence that an arrangement existed, ii) delivery had occurred, iii) our price was fixed and determinable and iv) collectability was reasonably assured. For periods beginning on January 1, 2018, we recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers
Expense Recognition	(l) Expense Recognition In 2018, we adopted ASC 340-40, Accounting for Other Assets and Deferred Costs
Income Taxes	(m) Income Taxes We account for income taxes in accordance with Codification Topic 740, Income Taxes
Stock-Based Compensation	(n) Stock-Based Compensation We account for stock-based compensation in accordance with Codification Topic 718, Compensation-Stock Compensation
Net (Loss) Income Per Common Share	(o) Net (Loss) Income Per Common Share Net (loss) income per common share has been computed in accordance with Codification Topic 260-10, Earnings Per Share. During the Three-Month During the Nine-Month Periods Ended Periods Ended 2018 2017 2018 2017 Weighted average number of shares outstanding 5,483,880 4,992,803 5,481,095 4,896,782 Effect of dilutive stock options - - - 102,463 Diluted number of shares outstanding 5,483,880 4,992,803 5,481,095 4,999,245 Outstanding stock options not included in the calculation because the effect would be anti-dilutive 489,000 367,000 489,000 63,000
Use of Estimates	(p) Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those estimates. Changes in estimates are recorded during the period in which they become known. Significant estimates include our inventory valuation, valuation of goodwill and long-lived assets, accrued expenses, costs of goods sold, and useful lives of intangible assets.
New Accounting Pronouncements	(q) New Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Schedule of financial assets measured at fair value on nonrecurring basis	As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 2,393,263 $ - $ - $ 2,393,263 Interest rate swaps $ - $ 98,390 $ - $ 98,390 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 3,798,811 $ - $ - $ 3,798,811 Liabilities: Interest rate swaps $ - $ (996 ) $ - $ (996 )
Schedule of sales to significant customers	During the Three-Month Periods Ended During the Nine-Month Periods Ended 2018 2017 2018 2017 Animal Health International, Inc. 50 % 44 % 42 % 42 % MWI Animal Health 23 % 22 % 22 % 23 % ANIMART LLC * 10 % 10 % * *Amount is less than 10%.
Schedule of accounts receivable due from significant customers	As of September 30, As of December 31, Animal Health International, Inc. 58 % 40 % MWI Animal Health 25 % 29 %
Schedule of weighted average and diluted number of shares outstanding	During the Three-Month During the Nine-Month Periods Ended Periods Ended 2018 2017 2018 2017 Weighted average number of shares outstanding 5,483,880 4,992,803 5,481,095 4,896,782 Effect of dilutive stock options - - - 102,463 Diluted number of shares outstanding 5,483,880 4,992,803 5,481,095 4,999,245 Outstanding stock options not included in the calculation because the effect would be anti-dilutive 489,000 367,000 489,000 63,000

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	9 Months Ended
	Sep. 30, 2018
Cash and Cash Equivalents [Abstract]
Schedule of cash and cash equivalents	As of September 30, 2018 As of December 31, 2017 Cash and cash equivalents $ 2,393,263 $ 3,798,811

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory [Abstract]
Schedule of inventory	As of September 30, As of December 31, Raw materials $ 416,139 $ 483,329 Work-in-process 1,310,526 1,349,649 Finished goods 523,277 216,754 Total $ 2,249,942 $ 2,049,732

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Prepaid Expenses and Other Current Assets [Abstract]
Schedule of prepaid expenses and other current assets	As of September 30, As of December 31, Other receivables (1) $ 390,207 $ 149,590 Prepaid expenses 296,380 130,813 Security deposits (2) 34,264 34,264 Total $ 720,851 $ 314,667 (1) This amount includes $250,000 due from a third party for the sale of assets. See Note 13. (2) This amount consists of the current portion of escrow funds held against certain construction performance requirements for our Nisin production facility.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	Estimated (in years) As of September 30, As of December 31, Laboratory and manufacturing equipment 3-10 $ 15,042,596 $ 5,511,452 Building and improvements 10-39 17,006,716 16,966,728 Office furniture and equipment 3-10 734,887 698,877 Construction in progress 34,786 8,315,436 Land 516,867 518,999 Property, plant and equipment, gross 33,335,852 32,011,492 Accumulated depreciation (6,863,398 ) (5,941,803 ) Property, plant and equipment, net $ 26,472,454 $ 26,069,689

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Intangible Assets [Abstract]
Schedule of intangible amortization expense	Period Amount Three-month period ending December 31, 2018 $ 4,776 Year ending December 31, 2019 19,104 Year ending December 31, 2020 19,104 Year ending December 31, 2021 19,104 Year ending December 31, 2022 19,104 After December 31, 2022 57,312 Total $ 138,504
Schedule of intangible assets	Intangible assets as of September 30, 2018 consisted of the following: Gross Carrying Value Accumulated Amortization Net Book Value Developed technology $ 184,100 $ (50,628 ) $ 133,472 Customer relationships 1,300 (357 ) 943 Non-compete agreements 5,640 (1,551 ) 4,089 Total $ 191,040 $ (52,536 ) $ 138,504 Intangible assets as of December 31, 2017 consisted of the following: Gross Carrying Value Accumulated Amortization Net Book Value Developed technology $ 184,100 $ (36,820 ) $ 147,280 Customer relationships 1,300 (260 ) 1,040 Non-compete agreements 5,640 (1,128 ) 4,512 Total $ 191,040 $ (38,208 ) $ 152,832

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Accounts Payable and Accrued Expenses [Abstract]
Schedule of accounts payable and accrued expenses	As of September 30, As of December 31, Accounts payable – capital $ 51,426 $ 641,389 Accounts payable – trade 515,785 580,456 Accrued payroll 281,036 254,743 Accrued professional fees 95,575 64,200 Accrued other 116,862 182,482 Total $ 1,060,684 $ 1,723,270

Bank Debt (Tables)

Bank Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Bank Debt [Abstract]
Schedule of interest rate swaps classified as level 2 fair value	During the Three-Month Periods Ended During the Nine-Month Periods Ended 2018 2017 2018 2017 Payments required by interest rate swaps $ 1,391 $ 8,115 $ 9,499 $ 29,834 Other comprehensive income, net of taxes $ 14,330 $ 1,824 $ 74,430 $ 3,419
Schedule of debt proceeds received and principal repayments made during the year	During the Three-Month Periods Ended September 30, 2018 September 30, 2017 Proceeds from Debt Issuance Debt Principal Repayments Proceeds from Debt Issuance Debt Principal Repayments Loan #1 $ - $ (16,219 ) $ - $ (15,264 ) Loan #2 - (21,279 ) - (20,343 ) Loan #3 426,499 - 2,184,343 - Loan #4 - (32,000 ) - - Loan #5 - (2,640 ) - (2,802 ) Total $ 426,499 $ (72,138 ) $ 2,184,313 $ (38,409 ) During the Nine-Month Periods Ended September 30, 2018 September 30, 2017 Proceeds from Debt Issuance Debt Principal Repayments Proceeds from Debt Issuance Debt Principal Repayments Loan #1 $ - $ (47,995 ) $ - $ (45,168 ) Loan #2 - (63,837 ) - (61,029 ) Loan #3 426,499 - 2,684,343 - Loan #4 267,141 (64,000 ) - - Loan #5 - (8,055 ) 340,000 (5,784 ) Total $ 693,640 $ (183,887 ) $ 3,024,343 $ (111,981 )
Schedule of principal payments due under debt outstanding	Three-Months ending 12/31/2018 Year ending 12/31/2019 Year ending 12/31/2020 Year ending 12/31/2021 Year Ending 12/31/2022 After 12/31/2022 Total Loan #1 $ 16,881 $ 68,908 $ 493,696 $ - $ - $ - $ 579,485 Loan #2 22,260 89,997 94,005 98,538 103,077 1,848,151 2,256,028 Loan #3 (1) 140,714 562,857 562,857 562,857 562,857 1,547,858 3,940,000 Loan #4 (1) 32,000 128,000 128,000 128,000 128,000 1,952,000 2,496,000 Loan #5 (2) 2,874 11,812 12,332 12,874 13,441 270,000 323,333 Total $ 214,729 $ 861,574 $ 1,290,890 $ 802,269 $ 807,375 $ 5,618,009 $ 9,594,846 Debt Issuance Costs (117,355 ) Total $ 9,477,491 (1) These notes bear interest at a variable rate equal to the one-month LIBOR plus a margin of 2.25%. Figures in this table are estimated using an interest rate of approximately 4.35%. The actual interest rate and principal payments will be different. (2) This note bears interest at a variable rate equal to the one-month LIBOR plus a margin of 2.25%. Figures in this table are estimated using an interest rate of approximately 4.31%. The actual interest rate and principal payments will be different.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Stockholders' Equity [Abstract]
Schedule of activity under the stock option plans	2000 Plan 2010 Plan 2017 Plan Weighted Aggregate Intrinsic Value (1) Outstanding at December 31, 2016 126,500 124,500 - $ 3.89 $ 516,990 Grants - 141,000 - $ 5.92 Terminations (5,000 ) (16,000 ) - $ 5.68 Exercises (4,000 ) (7,000 ) - $ 3.47 Outstanding at December 31, 2017 117,500 242,500 - $ 4.58 $ 1,513,980 Grants - 44,500 122,500 $ 7.39 Terminations - (15,000 ) (11,000 ) $ 6.55 Exercises (10,000 ) (2,000 ) - $ 3.38 Outstanding at September 30, 2018 107,500 270,000 111,500 $ 5.47 $ 1,400,530 Vested at September 30, 2018 107,500 36,500 - $ 2.59 $ 827,070 Vested and expected to vest at September 30, 2018 107,500 270,000 111,500 $ 5.47 $ 1,400,530 Reserved for future grants - 1,000 188,500
Schedule of fair value stock option grant using black-scholes option valuation model with the weighted-average assumptions	During the Three-Month Period Ended September 30, 2018 During the Nine-Month Period Ended September 30, 2018 During the Year Ended December 31, 2017 Risk-free interest rate 2.5 % 2.6 % 1.9 % Dividend yield 0 % 0 % 0 % Expected volatility 57 % 57 % 61 % Expected life 6.5 years 6.5 years 6.5 years

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2018
Major Product Category [Member]
Disaggregation of Revenue [Line Items]
Schedule of revenue disaggregated by geographic area and major product category	During the Three-Month Period Ended September 30, During the Nine-Month Period Ended September 30, 2018 2018 First Defense Ò $ 2,118,655 $ 7,783,006 Other animal health 35,095 266,475 Total product sales $ 2,153,750 $ 8,049,481
Geographical [Member]
Disaggregation of Revenue [Line Items]
Schedule of revenue disaggregated by geographic area and major product category	During the Three-Month Period Ended September 30, During the Nine-Month Period Ended September 30, 2018 2018 United States $ 1,893,483 $ 7,033,232 Other 260,267 1,016,249 Total product sales $ 2,153,750 $ 8,049,481

Other Expenses, Net (Tables)

Other Expenses, Net (Tables)	9 Months Ended
	Sep. 30, 2018
Other Expenses, Net [Abstract]
Schedule of other expenses, net	During the Three-Month Periods Ended During the Nine-Month Periods Ended 2018 2017 2018 2017 Interest expense $ 109,651 $ 53,168 $ 311,934 $ 136,563 Interest income (3,237 ) (2,983 ) (10,270 ) (15,358 ) Other gains - (947 ) - (5,328 ) Other expenses, net $ 106,414 $ 49,238 $ 301,664 $ 115,877

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Assets:
Cash and money market accounts	$ 2,393,263	$ 3,798,811
Interest rate swaps	98,390
Liabilities:
Interest rate swaps		(996)
Level 1 [Member]
Assets:
Cash and money market accounts	2,393,263	3,798,811
Interest rate swaps
Liabilities:
Interest rate swaps
Level 2 [Member]
Assets:
Cash and money market accounts
Interest rate swaps	98,390
Liabilities:
Interest rate swaps		(996)
Level 3 [Member]
Assets:
Cash and money market accounts
Interest rate swaps
Liabilities:
Interest rate swaps

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1)	3 Months Ended			9 Months Ended
	Sep. 30, 2018		Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Animal Health International, Inc. [Member]
Revenue, Major Customer [Line Items]
Concentration risk percentage	50.00%		44.00%	42.00%	42.00%
MWI Animal Health [Member]
Revenue, Major Customer [Line Items]
Concentration risk percentage	23.00%		22.00%	22.00%	23.00%
ANIMART LLC [Member]
Revenue, Major Customer [Line Items]
Concentration risk percentage		[1]	10.00%	10.00%		[1]
[1]	Amount is less than 10%.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2)	Sep. 30, 2018	Dec. 31, 2017
Animal Health International, Inc. [Member]
Revenue, Major Customer [Line Items]
Accounts receivable due from significant customers	58.00%	40.00%
MWI Animal Health [Member]
Revenue, Major Customer [Line Items]
Accounts receivable due from significant customers	25.00%	29.00%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 3) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Summary of Significant Accounting Policies [Abstract]
Weighted average number of shares outstanding	5,483,880	4,992,803	5,481,095	4,896,782
Effect of dilutive stock options				102,463
Diluted number of shares outstanding	5,483,880	4,992,803	5,481,095	4,999,245
Outstanding stock options not included in the calculation because the effect would be anti-dilutive	489,000	367,000	489,000	63,000

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Dec. 31, 2017
Summary of Significant Accounting Policies (Textual)
Federal deposit insurance corporation limits	$ 250,000		$ 250,000
Property, plant and equipment, description			The facility we have constructed to produce the active pharmaceutical ingredient, Nisin, is being depreciated over 39 years from when a certificate of occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin production facility when it was placed in service during the third quarter of 2018. Approximately 89% of these assets are being depreciated over ten years.
Concentration risk percentage, description			Sales to significant customers that amounted to 10% or more of total product sales.
U.S. government aggregated amount	2,140,960		$ 2,140,960			$ 3,546,529
Advertising expenses	3,900	$ 15,526	26,895	$ 47,863
Deferred tax assets					$ 563,252
Stock-based compensation	89,706	$ 46,922	257,697	$ 148,035
Increase in valuation allowance	315,725
Total valuation allowance	$ 878,977		$ 878,977

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Schedule of cash and cash equivalents
Cash and cash equivalents	$ 2,393,263	$ 3,798,811	$ 2,305,264	$ 5,150,344

Cash and Cash Equivalents (De_2

Cash and Cash Equivalents (Details Textual)	9 Months Ended
	Sep. 30, 2018
Cash and Cash Equivalents (Textual)
Debt covenant, description	Debt covenant to maintain at least $2,000,000 of otherwise unrestricted cash, cash equivalents and short-term investments.

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Schedule of inventory
Raw materials	$ 416,139	$ 483,329
Work-in-process	1,310,526	1,349,649
Finished goods	523,277	216,754
Total	$ 2,249,942	$ 2,049,732

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($)		Sep. 30, 2018	Dec. 31, 2017
Prepaid Expenses and Other Current Assets [Abstract]
Other receivables	[1]	$ 390,207	$ 149,590
Prepaid expenses		296,380	130,813
Security deposits	[2]	34,264	34,264
Total		$ 720,851	$ 314,667
[1]	This amount includes $250,000 due from a third party for the sale of assets. See Note 13.
[2]	This amount consists of the current portion of escrow funds held against certain construction performance requirements for our Nisin production facility.

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets (Details Textual)	Sep. 30, 2018USD ($)
Prepaid Expenses and Other Current Assets [Abstract]
Due from a third party	$ 250,000

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 33,335,852	$ 32,011,492
Accumulated depreciation	(6,863,398)	(5,941,803)
Property, plant and equipment, net	26,472,454	26,069,689
Laboratory and manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 15,042,596	5,511,452
Laboratory and manufacturing equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives	3 years
Laboratory and manufacturing equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives	10 years
Building and improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 17,006,716	16,966,728
Building and improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives	10 years
Building and improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives	39 years
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 734,887	698,877
Office furniture and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives	3 years
Office furniture and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives	10 years
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 34,786	8,315,436
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 516,867	$ 518,999

Property, Plant and Equipment_3

Property, Plant and Equipment (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment (Textual)
Property, plant and equipment, disposals	$ 18,554	$ 435,448

Business Acquisition (Details)

Business Acquisition (Details) - USD ($)	Jan. 04, 2016	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Sep. 30, 2016
Business Acquisition (Textual)
Total purchase price	$ 532,000
Amount paid on acquisition	368,000
Technology transfer payment					$ 97,000
Aggregate royalties payment	67,000
Estimated fair values of accounts payable and accrued expenses		$ 10,000		$ 18,000
Royalty expense		$ 12,046	$ 6,836
Estimated fair values of inventory	113,000
Estimated fair values of machinery and equipment	132,000
Estimated fair values of intangible assets	191,000
Estimated fair values of goodwill	$ 96,000

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Summary of intangible amortization expense
Three-month period ending December 31, 2018	$ 4,776
Year ending December 31, 2019	19,104
Year ending December 31, 2020	19,104
Year ending December 31, 2021	19,104
Year ending December 31, 2022	19,104
After December 31, 2022	57,312
Total	$ 138,504	$ 152,832

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 191,040	$ 191,040
Accumulated Amortization	(52,536)	(38,208)
Net Book Value	138,504	152,832
Developed technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	184,100	184,100
Accumulated Amortization	(50,628)	(36,820)
Net Book Value	133,472	147,280
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,300	1,300
Accumulated Amortization	(357)	(260)
Net Book Value	943	1,040
Non-compete agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	5,640	5,640
Accumulated Amortization	(1,551)	(1,128)
Net Book Value	$ 4,089	$ 4,512

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Intangible Assets (Textual)
Intangible amortization expense	$ 4,776	$ 4,776	$ 14,328	$ 14,328
Intangible asset amortized, useful lives			10 years
Net value	$ 138,504		$ 138,504		$ 152,832

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable - capital	$ 51,426	$ 641,389
Accounts payable - trade	515,785	580,456
Accrued payroll	281,036	254,743
Accrued professional fees	95,575	64,200
Accrued other	116,862	182,482
Total	$ 1,060,684	$ 1,723,270

Bank Debt (Details)

Bank Debt (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Bank Debt [Abstract]
Payments required by interest rate swaps	$ 1,391	$ 8,115	$ 9,499	$ 29,834
Other comprehensive income, net of taxes	$ 14,330	$ 1,824	$ 74,430	$ 3,419

Bank Debt (Details 1)

Bank Debt (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Debt Instrument [Line Items]
Proceeds from debt issuance	$ 426,499	$ 2,184,343	$ 693,640	$ 3,024,343
Debt Principal Repayments	(72,138)	(38,409)	(183,887)	(111,981)
Loan #1 [Member]
Debt Instrument [Line Items]
Proceeds from debt issuance
Debt Principal Repayments	(16,219)	(15,264)	(47,995)	(45,168)
Loan #2 [Member]
Debt Instrument [Line Items]
Proceeds from debt issuance
Debt Principal Repayments	(21,279)	(20,343)	(63,837)	(61,029)
Loan #3 [Member]
Debt Instrument [Line Items]
Proceeds from debt issuance	426,499	2,184,343	426,499	2,684,343
Debt Principal Repayments
Loan #4 [Member]
Debt Instrument [Line Items]
Proceeds from debt issuance			267,141
Debt Principal Repayments	(32,000)		(64,000)
Loan #5 [Member]
Debt Instrument [Line Items]
Proceeds from debt issuance				340,000
Debt Principal Repayments	$ (2,640)	$ (2,802)	$ (8,055)	$ (5,784)

Bank Debt (Details 2)

Bank Debt (Details 2)	Sep. 30, 2018USD ($)
Debt Instrument [Line Items]
Three-Months ending 12/31/2018	$ 214,729
Year ending 12/31/2019	861,574
Year ending 12/31/2020	1,290,890
Year ending 12/31/2021	802,269
Year ending 12/31/2022	807,375
After 12/31/2022	5,618,009
Subtotal	9,594,846
Debt Issuance Costs	(117,355)
Total	9,477,491
Loan #1 [Member]
Debt Instrument [Line Items]
Three-Months ending 12/31/2018	16,881
Year ending 12/31/2019	68,908
Year ending 12/31/2020	493,696
Year ending 12/31/2021
Year ending 12/31/2022
After 12/31/2022
Subtotal	579,485
Loan #2 [Member]
Debt Instrument [Line Items]
Three-Months ending 12/31/2018	22,260
Year ending 12/31/2019	89,997
Year ending 12/31/2020	94,005
Year ending 12/31/2021	98,538
Year ending 12/31/2022	103,077
After 12/31/2022	1,848,151
Subtotal	2,256,028
Loan #3 [Member]
Debt Instrument [Line Items]
Three-Months ending 12/31/2018	140,714	[1]
Year ending 12/31/2019	562,857	[1]
Year ending 12/31/2020	562,857	[1]
Year ending 12/31/2021	562,857	[1]
Year ending 12/31/2022	562,857	[1]
After 12/31/2022	1,547,858	[1]
Subtotal	3,940,000	[1]
Loan #4 [Member]
Debt Instrument [Line Items]
Three-Months ending 12/31/2018	32,000	[1]
Year ending 12/31/2019	128,000	[1]
Year ending 12/31/2020	128,000	[1]
Year ending 12/31/2021	128,000	[1]
Year ending 12/31/2022	128,000	[1]
After 12/31/2022	1,952,000	[1]
Subtotal	2,496,000	[1]
Loan #5 [Member]
Debt Instrument [Line Items]
Three-Months ending 12/31/2018	2,874	[2]
Year ending 12/31/2019	11,812	[2]
Year ending 12/31/2020	12,332	[2]
Year ending 12/31/2021	12,874	[2]
Year ending 12/31/2022	13,441	[2]
After 12/31/2022	270,000	[2]
Subtotal	$ 323,333	[2]
[1]	These notes bear interest at a variable rate equal to the one-month LIBOR plus a margin of 2.25%. Figures in this table are estimated using an interest rate of approximately 4.35%. The actual interest rate and principal payments will be different.
[2]	This note bears interest at a variable rate equal to the one-month LIBOR plus a margin of 2.25%. Figures in this table are estimated using an interest rate of approximately 4.31%. The actual interest rate and principal payments will be different.

Bank Debt (Details Textual)

Bank Debt (Details Textual)	3 Months Ended				9 Months Ended
	Mar. 31, 2017USD ($)ft²CreditFacilities	Mar. 31, 2016USD ($)CreditFacilities	Sep. 30, 2015USD ($)	Sep. 30, 2010USD ($)	Sep. 30, 2018USD ($)CreditFacilities	Sep. 30, 2017USD ($)
Bank Debt (Textual)
Number of credit facilities | CreditFacilities					5
Debt issue costs					$ 522	$ 63,358
Unrestricted cash, cash equivalents and short-term investments					$ 2,000,000
Credit Facilities [Member]
Bank Debt (Textual)
Number of credit facilities | CreditFacilities	2	2
Credit facility aggregate value	$ 6,500,000	$ 4,500,000
Variable interest rate with LIBOR, description					These notes bear interest at a variable rate equal to the one-month LIBOR plus a margin of 2.25%.
Variable interest rate					4.35%
Debt issue costs	66,622	$ 46,734	$ 34,125	$ 26,489
Credit Facilities One [Member]
Bank Debt (Textual)
Variable interest rate with LIBOR, description					This note bears interest at a variable rate equal to the one-month LIBOR plus a margin of 2.25%.
Variable interest rate					4.31%
Interest rate swaps [Member]
Bank Debt (Textual)
Variable interest rate with LIBOR, description					Interest rate exposures on Loan #1 and Loan #2 with interest rate swap agreements that effectively converted floating interest rates based on the one-month LIBOR plus a margin of 3.25% and 2.25% to the fixed rates of 6.04% and 4.38%, respectively. As of September 30, 2018, the variable rates on these two mortgage notes were approximately 5.40% and 4.43%, respectively.
Original notional amount					$ 2,835,513
Interest rate swaps [Member] | Loan One [Member]
Bank Debt (Textual)
Variable interest rate					5.40%
Original notional amount					$ 1,000,000
Interest rate swaps [Member] | Mortgage Loan Two [Member]
Bank Debt (Textual)
Variable interest rate					4.43%
Original notional amount					$ 2,500,000
TD Bank N.A [Member] | Loan One [Member]
Bank Debt (Textual)
Maximum limit on issuance of loan, rate				80.00%
Proceeds from issuance of loan				$ 1,000,000
Interest payments, term				10 years
Loan amortization, term				15 years
Balloon principal payment				$ 451,885
Balloon principal payment due, description				Due during the third quarter of 2020.
Outstanding amount of loan					579,485
TD Bank N.A [Member] | Mortgage Loan Two [Member]
Bank Debt (Textual)
Proceeds from issuance of loan			$ 2,500,000
Interest payments, term			10 years
Loan amortization, term			20 years
Balloon principal payment			$ 1,550,000
Balloon principal payment due, description			Due during the third quarter of 2025.
Outstanding amount of loan					$ 2,256,028
TD Bank N.A [Member] | Construction Loan Three [Member]
Bank Debt (Textual)
Maximum limit on issuance of loan, rate					80.00%
Proceeds from issuance of loan					$ 3,940,000
Loan amortization, term					7 years
Outstanding amount of loan					$ 3,940,000
Variable interest rate with LIBOR, description					Variable rate equal to the one-month LIBOR (adjusted at each monthly payment date) plus a margin of 2.25% (which was equal to approximately 4.35% for the one-month period beginning October 1, 2018) through September 2018.
Loan conversion, term					7 years
TD Bank N.A [Member] | Construction Loan Four [Member]
Bank Debt (Textual)
Maximum limit on issuance of loan, description					Not to exceed 80% (75% prior to the 2017 amendments).
Proceeds from issuance of loan					$ 2,560,000
Interest payments, term					10 years
Loan amortization, term					20 years
Balloon principal payment					$ 1,408,000
Balloon principal payment due, description					Due during the first quarter of 2027.
Outstanding amount of loan					$ 2,496,000
Variable interest rate with LIBOR, description					Variable rate equal to the one-month LIBOR (adjusted at each monthly payment date) plus a margin of 2.25% (which was equal to approximately 4.35% for the one-month period beginning October 1, 2018) through March 2018.
TD Bank N.A [Member] | Mortgage Loan Five [Member]
Bank Debt (Textual)
Proceeds from issuance of loan	$ 340,000
Interest payments, term	10 years
Loan amortization, term	20 years
Balloon principal payment	$ 206,000
Balloon principal payment due, description	Due during the first quarter of 2027.
Outstanding amount of loan					$ 323,333
Variable interest rate with LIBOR, description	Variable rate equal to the one-month LIBOR (adjusted at each monthly payment date) plus a margin of 2.25% (which was equal to approximately 4.31% for the one-month period beginning September 16, 2018).
Warehouse and storage facility | ft²	4,114
TD Bank N.A [Member] | Credit Facilities [Member]
Bank Debt (Textual)
Credit facility aggregate value				$ 500,000
Variable interest rate with LIBOR, description				Interest on borrowings against the line of credit is variable at the higher of 4.25% per annum or the one-month LIBOR plus 3.5% per annum.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Stock Option [Member] - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price, Outstanding, Beginning		$ 4.58	$ 3.89
Weighted Average Exercise Price, Grants		7.39	5.92
Weighted Average Exercise Price, Terminations		6.55	5.68
Weighted Average Exercise Price, Exercises		3.38	3.47
Weighted Average Exercise Price, Outstanding, Ending		5.47	$ 4.58
Weighted Average Exercise Price, Vested		2.59
Weighted average exercise price, Vested and expected to vest		$ 5.47
Aggregate Intrinsic Value, Outstanding, Beginning	[1]	$ 1,513,980	$ 516,990
Aggregate Intrinsic Value, Outstanding, Ending	[1]	1,400,530	$ 1,513,980
Aggregate Intrinsic Value, Vested	[1]	827,070
Aggregate Intrinsic Value, Vested and expected to vest	[1]	$ 1,400,530
2000 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, Beginning balance		117,500	126,500
Grants
Terminations			(5,000)
Exercises		(10,000)	(4,000)
Outstanding, Ending balance		107,500	117,500
Vested		107,500
Vested and expected to vest		107,500
Reserved for future grants
2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, Beginning balance		242,500	124,500
Grants		44,500	141,000
Terminations		(15,000)	(16,000)
Exercises		(2,000)	(7,000)
Outstanding, Ending balance		270,000	242,500
Vested		36,500
Vested and expected to vest		270,000
Reserved for future grants		1,000
2017 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, Beginning balance
Grants		122,500
Terminations		(11,000)
Exercises
Outstanding, Ending balance		111,500
Vested
Vested and expected to vest		111,500
Reserved for future grants		188,500
[1]	Intrinsic value is the difference between the fair market value as of the date indicated and as of the date of the option grant.

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Stockholders' Equity [Abstract]
Risk-free interest rate	2.50%	2.60%	1.90%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	57.00%	57.00%	61.00%
Expected life	6 years 6 months	6 years 6 months	6 years 6 months

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual)

Feb. 03, 2016USD ($)$ / sharesshares

Sep. 30, 1995$ / shares

Dec. 21, 2017USD ($)$ / sharesshares

Jul. 27, 2017USD ($)Investors$ / sharesshares

Jun. 30, 2017shares

Oct. 21, 2016USD ($)$ / sharesshares

Oct. 28, 2015USD ($)

Jun. 30, 2010shares

Jun. 30, 2000shares

Sep. 30, 2018USD ($)Employee$ / sharesshares

Sep. 30, 2017USD ($)$ / shares

Dec. 31, 2017Employee$ / sharesshares

Jun. 14, 2018shares

Dec. 31, 2016$ / shares

Jun. 15, 2016shares

Jun. 30, 2001shares

Stockholders' Equity (Textual)

Potential issuance or sale of equity | $

$ 10,000,000

Gross proceeds | $

$ 5,900,000

$ 3,050,000

Net proceeds | $

$ 5,313,000

$ 2,734,000

Common stock shares sold

1,123,810

417,807

Sale of stock, per share | $ / shares

$ 5.25

$ 7.30

Common stock, shares authorized

11,000,000

8,000,000

Stock option and incentive plan, description

We currently match 100% of the first 3% of each employee's salary that is contributed to the Plan and 50% of the next 2% of each employee's salary that is contributed to the Plan.

Proceeds from exercise of stock options | $

$ 15,500

$ 16,500

Stock Options Granted [Member]

Stockholders' Equity (Textual)

Stock option granted during the period

167,000

141,000

Private Placement [Member]

Stockholders' Equity (Textual)

Gross proceeds | $

$ 3,464,000

Net proceeds | $

$ 3,161,000

Common stock shares sold

659,880

Closing share price | $ / shares

$ 5.25

Minimum [Member]

Stockholders' Equity (Textual)

Common stock, shares authorized

8,000,000

8,000,000

Maximum [Member]

Stockholders' Equity (Textual)

Common stock, shares authorized

11,000,000

10,000,000

Investors [Member]

Stockholders' Equity (Textual)

Gross proceeds | $

$ 1,050,000

Net proceeds | $

$ 1,034,000

Number of related investors | Investors

2

Common stock shares issued

200,000

Closing share price | $ / shares

$ 5.25

Stock Option [Member]

Stockholders' Equity (Textual)

Number of employee exercised stock options | Employee

6

Aggregate intrinsic value of options exercised | $

$ 46,790

$ 43,470

Weighted-average grant date fair values of options granted | $ / shares

$ 4.21

$ 3.51

Total unrecognized stock-based compensation related to non-vested stock options | $

$ 795,891

Share-based payment, description

Stock options covering 12,000 shares. Four thousand of these options were exercised for cash, resulting in total proceeds of $15,490, and 8,000 of these options were exercised by the surrender of 3,469 shares of common stock with a fair market value of $25,040 at the time of exercise and $10 in cash.

Exercised stock options covering 11,000 shares for cash, resulting in total proceeds of $49,560.

Exercise prices of options outstanding | $ / shares

$ 5.47

$ 4.58

$ 3.89

Weighted average remaining life of unrecognized stock-based compensation related to non-vested

1 year 11 months

Stock Option [Member] | Minimum [Member]

Stockholders' Equity (Textual)

Sale of stock, per share | $ / shares

$ 6.81

5.33

Exercise prices of options outstanding | $ / shares

1.70

Stock Option [Member] | Maximum [Member]

Stockholders' Equity (Textual)

Sale of stock, per share | $ / shares

8.43

$ 8.90

Exercise prices of options outstanding | $ / shares

$ 8.90

Stock Option [Member] | Employee [Member]

Stockholders' Equity (Textual)

Number of stock options exercised

12,000

Proceeds from exercise of stock options | $

$ 15,490

Number of employee exercised stock options | Employee

4

2000 Plan [Member] | Stock Option [Member]

Stockholders' Equity (Textual)

Common stock reserved for issuance under the plan

Number of stock options exercised

10,000

4,000

Stock option granted during the period

2000 Plan [Member] | Stock Option [Member] | Employee [Member]

Stockholders' Equity (Textual)

Stock option and incentive plan, description

No less than 85% of fair market value on the date of grant in the case of non-qualified stock options.

Common stock reserved for issuance under the plan

250,000

500,000

Stock option expiration period

10 years

5 years 6 months

Weighted average remaining life of options exercisable

9 months

Option expiry date

Feb. 28, 2010

2010 Plan [Member] | Stock Option [Member]

Stockholders' Equity (Textual)

Common stock reserved for issuance under the plan

1,000

Number of stock options exercised

2,000

7,000

Stock option granted during the period

44,500

141,000

2010 Plan [Member] | Stock Option [Member] | Employee [Member]

Stockholders' Equity (Textual)

Common stock reserved for issuance under the plan

300,000

Stock option expiration period

10 years

Share-based payment, description

The 2010 Plan expires in June 2020, after which date no further options could be granted under the 2010 Plan.

Option expiry date

Jun. 30, 2020

Common Stock Rights Plan [Member]

Stockholders' Equity (Textual)

Share-based payment, description

At any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of 50% or more of the outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment).

Common stock purchase price | $ / shares

$ 70

$ 70

Employee stock, plan description

The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date).

Our Board of Directors also has voted to authorize amendments to increase the ownership threshold for determining "Acquiring Person" status to 20%. During the second quarter of 2015, our Board of Directors also voted to authorize an amendment to remove a provision that prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than 20% of our stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with pre-existing directors.

Sale of common stock, description

The Company should consolidate or merge with any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company's common stock were changed or exchanged into the securities of any other entity, or if more than 50% of the Company's assets or earning power were sold.

Outstanding rights price per share | $ / shares

$ 0.005

2017 Plan [Member] | Stock Option [Member]

Stockholders' Equity (Textual)

Common stock reserved for issuance under the plan

188,500

Number of stock options exercised

Stock option granted during the period

122,500

2017 Plan [Member] | Stock Option [Member] | Employee [Member]

Stockholders' Equity (Textual)

Common stock reserved for issuance under the plan

300,000

Stock option expiration period

10 years

Option expiry date

Mar. 31, 2027

Revenue (Details)

Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Total product sales	$ 2,153,750	$ 2,004,961	$ 8,049,481	$ 7,298,496
United States [Member]
Disaggregation of Revenue [Line Items]
Total product sales	1,893,483		7,033,232
Other States [Member]
Disaggregation of Revenue [Line Items]
Total product sales	$ 260,267		$ 1,016,249

Revenue (Details 1)

Revenue (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Total product sales	$ 2,153,750	$ 2,004,961	$ 8,049,481	$ 7,298,496
First Defense product line [Member]
Disaggregation of Revenue [Line Items]
Total product sales	2,118,655		7,783,006
Other animal health [Member]
Disaggregation of Revenue [Line Items]
Total product sales	$ 35,095		$ 266,475

Revenue (Details Textual)

Revenue (Details Textual)	3 Months Ended	9 Months Ended
	Mar. 31, 2018	Sep. 30, 2018
Revenue (Textual)
Revenue, description	We had a backlog of orders (representing purchase orders received from customers which were not fulfilled or paid) worth approximately $1,245,000.	We had a backlog of orders for Tri-Shield First Defense® worth approximately $301,000.

Gain on Sale of Assets (Details

Gain on Sale of Assets (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Gain on Sale of Assets (Textual)
Sale of technology	$ 700,000
Upfront payment received		$ 250,000
Second Payment [Member] | Third quarter of 2019 [Member]
Gain on Sale of Assets (Textual)
Upfront payment received		250,000
Third Payment [Member] | Fourth quarter of 2019 [Member]
Gain on Sale of Assets (Textual)
Upfront payment received		$ 200,000

Other Expenses, Net (Details)

Other Expenses, Net (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Other Expenses, Net [Abstract]
Interest expense	$ 109,651	$ 53,168	$ 311,934	$ 136,563
Interest income	(3,237)	(2,983)	(10,270)	(15,358)
Other gains		(947)		(5,328)
Other expenses, net	$ 106,414	$ 49,238	$ 301,664	$ 115,877

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2004	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018
Income Taxes (Textual)
Income tax (benefit) expense	$ (5,598)	$ (192,303)		$ 447,075	$ 28,108
State net operating loss carryforwards	429,000			429,000
Federal net operating loss carryforwards	1,700,000			1,700,000
Federal general business tax credit carryforwards	335,000			$ 335,000
Tax credit carryforward, description				Federal net operating loss carryforwards of approximately $1,700,000 that expire in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards of approximately $429,000 that expire in 2037 (if not utilized before then). Additionally, we had federal general business tax credit carryforwards of approximately $335,000 that expire in 2027 through 2037 (if not utilized before then) and state tax credit carryforwards of approximately $294,000 that expire in 2023 through 2037 (if not utilized before then)
State tax credit carryforwards	$ 294,000			$ 294,000
Intangible asset			$ 965,000
Amortization period			15 years
(Loss) income before income taxes, rate	2.00%	36.00%		54.00%	51.00%
Capitalized and depreciated over statutory periods	$ 820,000			$ 820,000
Deferred tax assets						$ 563,252
Increase in valuation allowance	315,725
Total valuation allowance	878,977			$ 878,977
Maximum [Member]
Income Taxes (Textual)
U.S. federal corporate tax rate				34.00%
Minimum [Member]
Income Taxes (Textual)
U.S. federal corporate tax rate				21.00%
Investment [Member]
Income Taxes (Textual)
Investment in small-scale facility	$ 1,112,000			$ 1,112,000

Contingent Liabilities and Co_2

Contingent Liabilities and Commitments (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Contingent Liabilities and Commitments (Textual)
Termination fee	$ 100,000
Purchase of inventory	682,000
Other obligations	142,000
Milestone payment		$ 150,000
Royalty, percentage			4.00%
Growth assumption, percentage				6.00%
Royalty payment to Baylor	7,500	$ 5,000
Royalties due for 2017	5,000
Royalties due for 2018	10,000
Royalties due for 2019	15,000
Royalties due for 2020	20,000
Royalties due for 2021	25,000
Capital expenditures	$ 77,000

Segment Information (Details)

Segment Information (Details) - Sales Revenue, Net [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment Information (Textual)
Concentration risk percentage	98.00%	98.00%	97.00%	94.00%
U.S. dairy and beef industries [Member]
Segment Information (Textual)
Concentration risk percentage	88.00%	87.00%	87.00%	83.00%
International dairy and beef [Member]
Segment Information (Textual)
Concentration risk percentage	12.00%	13.00%	13.00%	15.00%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Related Party Transactions (Textual)
Revenues from transactions with related party	$ 392,308	$ 465,670
Marketing-related payments	11,405	$ 3,168
Accounts receivable, related parties	$ 15,177		$ 14,176

Employee Benefits (Details)

Employee Benefits (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Employee Benefits (Textual)
Employee savings plan, description			All employees completing one month of service with the Company are eligible to participate.
Defined benefit plans general information, description			We currently match 100% of the first 3% of each employee's salary that is contributed to the Plan and 50% of the next 2% of each employee's salary that is contributed to the Plan.
Defined benefit plan benefits paid	$ 25,644	$ 21,083	$ 79,655	$ 64,105